Abstract
We studied 459 consecutive patients with hematologic malignancies, median age 44years (range, 15 to 71years), who underwent transplantation with grafts from identical sibling donors (SIB; n=176), matched unrelated donors (MUD; n=43), mismatched unrelated donors (mmUD; n=43), unrelated cord blood (UCB; n=105) or HLA-haploidentical family donors (HAPLO; n=92). Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate in the SIB recipients; antithymocyte globulin for the MUD, mmUD, and UCB recipients; and post-transplantation cyclophosphamide, cyclosporine, and mycophenolate in the HAPLO recipients. Conditioning regimens were mostly myeloablative (69%). Advanced disease phase was more frequent, but not significantly so, in the HAPLO and mmUD groups (P=08). Acute GVHD grade II-IV was significantly less frequent in the HAPLO, UCB, and MUD groups (14% to 21%) compared with the SIB (31%) and mmUD (42%) groups (P
| Original language | English |
|---|---|
| Pages (from-to) | 1573-1579 |
| Number of pages | 7 |
| Journal | Biology of Blood and Marrow Transplantation |
| Volume | 20 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - Oct 1 2014 |
Fingerprint
Keywords
- Allogeneic transplant
- Cord blood
- Haploidentical
- Unrelated
ASJC Scopus subject areas
- Transplantation
- Hematology
- Medicine(all)
Cite this
Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. / Raiola, Anna Maria; Dominietto, Alida; di Grazia, Carmen; Lamparelli, Teresa; Gualandi, Francesca; Ibatici, Adalberto; Bregante, Stefania; Van Lint, Maria Teresa; Varaldo, Riccardo; Ghiso, Anna; Gobbi, Marco; Carella, Angelo Michele; Signori, Alessio; Galaverna, Federica; Bacigalupo, Andrea.
In: Biology of Blood and Marrow Transplantation, Vol. 20, No. 10, 01.10.2014, p. 1573-1579.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts
AU - Raiola, Anna Maria
AU - Dominietto, Alida
AU - di Grazia, Carmen
AU - Lamparelli, Teresa
AU - Gualandi, Francesca
AU - Ibatici, Adalberto
AU - Bregante, Stefania
AU - Van Lint, Maria Teresa
AU - Varaldo, Riccardo
AU - Ghiso, Anna
AU - Gobbi, Marco
AU - Carella, Angelo Michele
AU - Signori, Alessio
AU - Galaverna, Federica
AU - Bacigalupo, Andrea
PY - 2014/10/1
Y1 - 2014/10/1
N2 - We studied 459 consecutive patients with hematologic malignancies, median age 44years (range, 15 to 71years), who underwent transplantation with grafts from identical sibling donors (SIB; n=176), matched unrelated donors (MUD; n=43), mismatched unrelated donors (mmUD; n=43), unrelated cord blood (UCB; n=105) or HLA-haploidentical family donors (HAPLO; n=92). Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate in the SIB recipients; antithymocyte globulin for the MUD, mmUD, and UCB recipients; and post-transplantation cyclophosphamide, cyclosporine, and mycophenolate in the HAPLO recipients. Conditioning regimens were mostly myeloablative (69%). Advanced disease phase was more frequent, but not significantly so, in the HAPLO and mmUD groups (P=08). Acute GVHD grade II-IV was significantly less frequent in the HAPLO, UCB, and MUD groups (14% to 21%) compared with the SIB (31%) and mmUD (42%) groups (P
AB - We studied 459 consecutive patients with hematologic malignancies, median age 44years (range, 15 to 71years), who underwent transplantation with grafts from identical sibling donors (SIB; n=176), matched unrelated donors (MUD; n=43), mismatched unrelated donors (mmUD; n=43), unrelated cord blood (UCB; n=105) or HLA-haploidentical family donors (HAPLO; n=92). Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate in the SIB recipients; antithymocyte globulin for the MUD, mmUD, and UCB recipients; and post-transplantation cyclophosphamide, cyclosporine, and mycophenolate in the HAPLO recipients. Conditioning regimens were mostly myeloablative (69%). Advanced disease phase was more frequent, but not significantly so, in the HAPLO and mmUD groups (P=08). Acute GVHD grade II-IV was significantly less frequent in the HAPLO, UCB, and MUD groups (14% to 21%) compared with the SIB (31%) and mmUD (42%) groups (P
KW - Allogeneic transplant
KW - Cord blood
KW - Haploidentical
KW - Unrelated
UR - http://www.scopus.com/inward/record.url?scp=84912523216&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84912523216&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2014.05.029
DO - 10.1016/j.bbmt.2014.05.029
M3 - Article
C2 - 24910379
AN - SCOPUS:84912523216
VL - 20
SP - 1573
EP - 1579
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
SN - 1083-8791
IS - 10
ER -